Form 4: Oramed Pharmaceuticals CFO Acquires 188,000 Restricted Stock Units
SEC Form 4
Oramed Pharmaceuticals' Chief Financial Officer, Avraham Gabay, acquired 188,000 restricted stock units (RSUs) on January 2, 2025.
Summary
- Avraham Gabay, the Chief Financial Officer of Oramed Pharmaceuticals, acquired 188,000 restricted stock units on January 2, 2025.
- These restricted stock units will vest in quarterly installments of approximately 15,666 over a three-year period starting January 1, 2025.
- The RSUs convert into Oramed Pharmaceuticals' common stock on a one-for-one basis.
- Following this transaction, Mr. Gabay beneficially owns 358,040 shares of common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.
Positives
- The acquisition of RSUs by the CFO demonstrates confidence in the company's future.
Future Outlook
The restricted stock units will vest over a three-year period, aligning the CFO's interests with the long-term performance of the company.
Industry Context
This type of equity compensation is common for executives in publicly traded companies, aligning their interests with shareholders.
Comparison to Industry Standards
- Equity-based compensation, such as RSUs, is a standard practice for executive compensation in the pharmaceutical industry.
- Companies like Teva Pharmaceuticals and Mylan (now Viatris) also use similar equity compensation plans to incentivize their executives.
- The vesting schedule of three years is also a common practice to ensure long-term commitment from the executive.
Stakeholder Impact
- The acquisition of RSUs by the CFO could be viewed positively by shareholders as it aligns management's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Start date for quarterly vesting of the restricted stock units. |
| 01/02/2025 | Date of the transaction where the CFO acquired the restricted stock units. |
| 01/06/2025 | Date the form was signed. |
Keywords
Oramed Pharmaceuticals, Restricted Stock Units, RSU, Beneficial Ownership, Avraham Gabay, CFO, Stock Acquisition, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.